



Company Announcement no. 22/2014

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, 2 September 2014

### **Warrant Programme - New Articles of Association**

In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of Directors of Veloxis Pharmaceuticals A/S has on 20 August 2014 issued 2,255,000 warrants for the subscription of nominally DKK 225,500 shares in the Company.

The amendment of the Articles of Association associated with the issue of warrants has today been registered with the Danish Business Authority. The new Articles of Association are for Veloxis Pharmaceuticals A/S are attached.

#### **For more information, please contact:**

Veloxis Pharmaceuticals A/S

Bill Polvino  
President & CEO  
Mobile: +1 917 647 9107  
Email: wjp@veloxis.com

Johnny Stilou  
EVP, Chief Financial Officer  
Mobile: +45 21 227 227  
Email: jst@veloxis.com

#### **About Veloxis Pharmaceuticals**

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company's lead product candidate is Envarsus® XR for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Salix, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit [www.veloxis.com](http://www.veloxis.com).